NAVB Bulls vs Bears 9/19/15

Bulls vs Bears updated 9/19/15

Bullish

• Manocept-Doxorubicin (MT-1001) conjugate selectively targets tumor-associated macrophages and kills cells via apoptosis
• Gross margins on Lymphoseek grew to 83% for the second quarter of 2015 compared to 74%
• Dual listing in TASE; started trading on 9/8/15
• Maintain goal to achieve break-even cash flow in first quarter 2016 
• Reiterate guidance for Lymphoseek revenue in 2015 is $10 million to $12 million ($4.2 million in Y 2014); over 100% increase. 
• Awarded NIH grants to explore new applications of the ManoceptTM platform for cardiovascular disease and rheumatoid arthritis (RA) totaling up to $2.0 million
• Lymphoseek injection is statistically less painful to patients compared to filtered Tc-99m Sulfur Colloid (fTcSC) as published 8/20/15;
• Incentive plan for new CEO tied to stock price (see news dated 10/15/14)
• Lymphoseek®Phase 3 NEO3-06 Clinical Trial in Oral Cavity Cancer of the Head and Neck met primary goal; 

Bearish

• Actual Q2 2015 Lymphoseek sales ($1.9M) did not track anticipated 28%  increase(or $2.8M);
• Expensive term loan ($50 million) with CRG (A term of six years, an interest only period for the first four years, and a 14% annual interest rate) see news dated 5/11/15, 
• NAV 4694 F-18 PET for AD on hold pending partner 
• NAV5001 (I-123) radiolabeled SPECT for PD, program terminated with Alseres Pharm.